Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.

Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.
C
C

Cigna

Ειδήσεις

Reuters - 17 ώρες πριν

U.S. STOCKS Morgan Stanley, Datadog, Berkshire Hathaway

BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Datadog, Berkshire Hathaway Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street jumped in upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided market sentiment.
A
A
C
G
T
U
U
D
Reuters - 19 ώρες πριν

U.S. STOCKS Health insurance firms, Super Micro, Datadog

BUZZ-U.S. STOCKS ON THE MOVE-Health insurance firms, Super Micro, Datadog Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Dow hit a record high in Wall Street's upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided sentiment.
A
A
C
G
H
S
T
U
U
Reuters - 23 ώρες πριν

Health insurance stocks gain as odds of Trump victory rise after shooting

BUZZ-Health insurance stocks gain as odds of Trump victory rise after shooting ** Shares of health insurers rise between 2.85% and 1.87% in premarket trading ** Humana HUM.N rises 2.85% to $393.10, UnitedHealth UNH.N gains 2.39% to $523.75, CVS CVS.N up 1.86% to $60.10, and Cigna CI.N up 1.87% to $341.06 ** After the events of the weekend, investors appear to believe that a Trump victory could be more likely in the November election, says Morningstar analyst Julie Utterback ** Former U.S.
C
Reuters - 4 ημέρες πριν

Chuck Close's estate settles lawsuit against Cigna over medical bills

Chuck Close's estate settles lawsuit against Cigna over medical bills By Jonathan Stempel NEW YORK, July 12 (Reuters) - The estate of Chuck Close, the artist known for massive photorealist portraits of himself and others, settled a lawsuit accusing Cigna CI.N of failing to pay hundreds of thousands of dollars for needed medical care in the last years of his life.
C
Reuters - 6 ημέρες πριν

CVS Health, Cigna down after report FTC to sue PBMs over insulin prices

BUZZ-CVS Health, Cigna down after report FTC to sue PBMs over insulin prices ** Shares of health insurers fall; CVS Health CVS.N down ~1% at $57.05 and Cigna CI.N slips 0.8% to $325.88 ** The U.S. Federal Trade Commission (FTC) plans to sue pharmacy-benefit managers (PBMs) CVS Health, Cigna and UnitedHealth UNH.N , a source familiar with the matter told Reuters ** The FTC is suing the companies over their tactics for negotiating prices for drugs, including insulin - source ** The FTC is also loo
C
S
Reuters - 6 ημέρες πριν

US FTC to sue drug middlemen over insulin prices, source says

UPDATE 5-US FTC to sue drug middlemen over insulin prices, source says Adds Novo declining comment, background on insulin By Jody Godoy and Mariam Sunny July 10 (Reuters) - The U.S. Federal Trade Commission is planning to sue UnitedHealth UNH.N , Cigna CI.N and CVS Health CVS.N over their tactics as middlemen in negotiating prices for drugs including insulin, a person familiar with the matter s aid on Wednesday.
C
S
Reuters - 6 ημέρες πριν

US FTC to sue drug middlemen over insulin prices, WSJ reports

US FTC to sue drug middlemen over insulin prices, WSJ reports July 10 (Reuters) - The U.S. Federal Trade Commission is planning to sue UnitedHealth UNH.N , Cigna CI.N and CVS Health CVS.N , the three largest pharmacy-benefit managers, over their tactics for negotiating prices for drugs including insulin, the Wall Street Journal reported on Wednesday, citing a person familiar with the matter.
C
Reuters - 6 ημέρες πριν

FTC To Sue Unitedhealth Group, Cigna Group And CVS Health Over Insulin Prices- WSJ

BRIEF-FTC To Sue Unitedhealth Group, Cigna Group And CVS Health Over Insulin Prices- WSJ July 10 (Reuters) - FTC TO SUE UNITEDHEALTH GROUP’S OPTUMRX, CIGNA GROUP’S EXPRESS SCRIPTS AND CVS HEALTH’S CAREMARK OVER INSULIN PRICES- WSJ Source text : https://tinyurl.com/2cap4863 Further company coverage: CI.N
C
Reuters - 1 εβδομάδα πριν

Middlemen have outsized influence on US drug prices, FTC says

UPDATE 2-Middlemen have outsized influence on US drug prices, FTC says Adds UnitedHealth comment in paragraph 6 By Ahmed Aboulenein and Jody Godoy WASHINGTON, July 9 (Reuters) - The consolidation of pharmacies and health insurance companies through years of dealmaking has led to a handful of pharmacy benefit managers exercising outsized influence over prescription drug prices, the U.S.
C
Reuters - 1 εβδομάδα πριν

PBMs slip after FTC indicates outsized influence of middlemen on US drug prices

BUZZ-PBMs slip after FTC indicates outsized influence of middlemen on US drug prices ** Shares of pharmacy benefit managers slip after the U.S. Federal Trade Commission says consolidation of pharmacies and health insurance companies through years of deal making has led to a handful of pharmacy benefit managers exercising outsized influence over prescription drug prices ** Shares of CVS CVS.N fall 1%, Humana HUM.N down 1.2% while UnitedHealth UNH.N marginally down ** Pharmacy benefit managers, or
C
Reuters - 1 εβδομάδα πριν

Why are US pharmacy benefit managers under fire?

EXPLAINER-Why are US pharmacy benefit managers under fire? By Ahmed Aboulenein WASHINGTON, July 9 (Reuters) - The U.S. Federal Trade Commission said on Tuesday in an interim report on its investigation into pharmacy benefit managers that healthcare consolidation has given the companies outsized influence over prescription drug prices that could warrant regulation.
C
Reuters - 1 εβδομάδα πριν

Middlemen have outsized influence on US drug prices due to market consolidation, FTC says

Middlemen have outsized influence on US drug prices due to market consolidation, FTC says By Ahmed Aboulenein and Jody Godoy WASHINGTON, July 9 (Reuters) - The consolidation of pharmacies and health insurance companies through years of deal making has led to a handful of pharmacy benefit managers exercising outsized influence over prescription drug prices, the U.S.
C
Reuters - 3 εβδομάδες πριν

U.S. Campbell Soup, Tesla, Walgreens

U.S. RESEARCH ROUNDUP-Campbell Soup, Tesla, Walgreens June 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Campbell Soup, Tesla and Walgreens, on Wednesday. HIGHLIGHTS * Campbell Soup Co CPB.N : JP Morgan raises to overweight from neutral * Kratos Defense and Security Solutions KTOS.O : BTIG initiates coverage with Neutral rating * Rocket Lab USA Inc RKLB.O : BTIG initiates coverage with Neutral rating * Tesla Inc
A
A
C
D
G
L
N
P
T
V
W
U
C
A
F
H
Reuters - 1 μήνα πριν

Cigna's medical use trends in line with projections for 2023, 2024 -GS conference

UPDATE 1-Cigna's medical use trends in line with projections for 2023, 2024 -GS conference Adds details from the conference call throughout By Amina Niasse and Pratik Jain NEW YORK, June 11 (Reuters) - Health insurer Cigna's CI.N medical use trends across its portfolio were in line with its expectations for 2023 and 2024, CFO Brian Evanko said on Tuesday, citing the company's lack of Medicaid management.
C
G
Reuters - 1 μήνα πριν

UnitedHealth hack impacted outpatient claims for Cigna - GS conference

UnitedHealth hack impacted outpatient claims for Cigna - GS conference NEW YORK, June 11 (Reuters) - Cigna's CFO Brian Evanko said the company's "outpatient dynamic" was impacted by the Change Healthcare hack which disrupted claims during the first quarter of 2024. The February ransomware attack on the largest U.S. insurer stole a "substantial portion" of personal data from American patients and disrupted provider payments.
C
Reuters - 1 μήνα πριν

AbbVie's tight grip on Humira market raises concerns about biosimilars

FOCUS-AbbVie's tight grip on Humira market raises concerns about biosimilars By Patrick Wingrove June 7 (Reuters) - AbbVie’s ABBV.N top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
A
C
P
T
F
Reuters - 2 μήνες πριν

U.S. Elevance Health, Wesco International, WW Grainger

U.S. RESEARCH ROUNDUP-Elevance Health, Wesco International, WW Grainger May 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies including Elevance Health, Wesco International and WW Grainger, on Thursday. HIGHLIGHTS * Cigna Group CI.N : JP Morgan raises target price to $435 from $432 * Elevance Health Inc ELV.N : JP Morgan raises target price to $631 from $628 * Uipath Inc PATH.N : TD Cowen cuts to hold from buy * Wesco Internati
A
C
C
E
F
S
A
E
H
W
A
L
U
Reuters - 2 μήνες πριν

U.S. AMC Networks, Permian Resources, Vital Energy

U.S. RESEARCH ROUNDUP-AMC Networks, Permian Resources, Vital Energy May 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMC Networks, Permian Resources and Vital Energy, on Monday. HIGHLIGHTS * AMC Networks AMCX.O : Moffettnathanson cuts target price by $1 to $13 * Celanese Corp CE.N : Jefferies raises target price to $170 from $155 * Permian Resources Corp PR.N : Gerdes Energy Research raises to buy from neutral
A
B
C
G
H
A
A
A
U
A
A
C
Reuters - 2 μήνες πριν

Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates

CORRECTED-UPDATE 2-Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates Corrects in paragraph 6 to say Cigna and Optum are covering two or three Humira biosimilars By Steven Scheer JERUSALEM, May 8 (Reuters) - Teva Pharmaceutical Industries TEVA.TA said it was set to launch its long awaited biosimilar of AbbVie's ABBV.N blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. The drugmaker also said late-stage results
C
T
Reuters - 2 μήνες πριν

U.S. Berkshire Hathaway, Parker-Hannifin, Quaker Houghton

U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Parker-Hannifin, Quaker Houghton May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Berkshire Hathaway, Parker-Hannifin and Quaker Houghton, on Monday. HIGHLIGHTS * Berkshire Hathaway BRKa.N : KBW raises target price to $660,000 from $645,000 * Essex Property Trust Inc ESS.N : Piper Sandler raises target price to $315 from $291 * Parker-Hannifin Corp PH.N : Jefferies cuts
A
C
E
G
E
C
C

Όροι

Δημοφιλή περιουσιακά στοιχεία

Δήλωση αποποίησης ευθύνης: Οι οντότητες του ομίλου XM Group παρέχουν υπηρεσίες σε βάση εκτέλεσης μόνο και η πρόσβαση στην ηλεκτρονική πλατφόρμα συναλλαγών μας που επιτρέπει στον ενδιαφερόμενο να δει ή/και να χρησιμοποιήσει το περιεχόμενο που είναι διαθέσιμο στην ιστοσελίδα μας ή μέσω αυτής, δε διαφοροποιεί ούτε επεκτείνει αυτές τις υπηρεσίες πέραν αυτού ούτε προορίζεται για κάτι τέτοιο. Η εν λόγω πρόσβαση και χρήση υπόκεινται σε: (i) Όρους και προϋποθέσεις, (ii) Προειδοποιήσεις κινδύνου και (iii) Πλήρη δήλωση αποποίησης ευθύνης. Ως εκ τούτου, το περιεχόμενο αυτό παρέχεται μόνο ως γενική πληροφόρηση. Λάβετε ιδιαιτέρως υπόψη σας ότι τα περιεχόμενα της ηλεκτρονικής πλατφόρμας συναλλαγών μας δεν αποτελούν παρότρυνση, ούτε προσφορά για να προβείτε σε οποιεσδήποτε συναλλαγές στις χρηματοπιστωτικές αγορές. Η πραγματοποίηση συναλλαγών στις χρηματοπιστωτικές αγορές ενέχει σημαντικό κίνδυνο για το κεφάλαιό σας.

Όλο το υλικό που δημοσιεύεται στην ηλεκτρονική πλατφόρμα συναλλαγών μας προορίζεται για εκπαιδευτικούς/ενημερωτικούς σκοπούς μόνο και δεν περιέχει, ούτε θα πρέπει να θεωρηθεί ότι περιέχει συμβουλές και συστάσεις χρηματοοικονομικές ή σε σχέση με φόρο επενδύσεων και την πραγματοποίηση συναλλαγών, ούτε αρχείο των τιμών διαπραγμάτευσής μας ούτε και προσφορά ή παρότρυνση για συναλλαγή οποιωνδήποτε χρηματοπιστωτικών μέσων ή ανεπιθύμητες προς εσάς προωθητικές ενέργειες.

Οποιοδήποτε περιεχόμενο τρίτων, καθώς και περιεχόμενο που εκπονείται από την ΧΜ, όπως απόψεις, ειδήσεις, έρευνα, αναλύσεις, τιμές, άλλες πληροφορίες ή σύνδεσμοι προς ιστότοπους τρίτων το οποίο περιέχεται σε αυτήν την ιστοσελίδα παρέχεται «ως έχει», ως γενικός σχολιασμός της αγοράς και δεν αποτελεί επενδυτική συμβουλή. Στον βαθμό που οποιοδήποτε περιεχόμενο ερμηνεύεται ως επενδυτική έρευνα, πρέπει να λάβετε υπόψη και να αποδεχτείτε ότι το περιεχόμενο δεν προοριζόταν και δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της επενδυτικής έρευνας και ως εκ τούτου, θα πρέπει να θεωρηθεί ως επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς. Παρακαλούμε εξασφαλίστε ότι έχετε διαβάσει και κατανοήσει τη Γνωστοποίησή μας περί Μη ανεξάρτητης επενδυτικής έρευνας και την Προειδοποίηση ρίσκου όσον αφορά τις παραπάνω πληροφορίες, τις οποίες μπορείτε να βρείτε εδώ.

Προειδοποίηση ρίσκου: Τα κεφάλαιά σας κινδυνεύουν. Τα προϊόντα με μόχλευση ενδέχεται να μην είναι κατάλληλα για όλους. Παρακαλούμε λάβετε υπόψη σας τη Γνωστοποίηση ρίσκου.